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 Synopsis: Awareness of HPV infection and its consequences among Latvian 
adolescents was poor, which might explain the low levels of HPV vaccine uptake in 
this population. 
 ABSTRACT 
Objective: To evaluate awareness of HPV and its vaccine among Latvian 
adolescents. 
Methods: A cross-sectional survey was conducted in a 2-week period in September 
2015 among 270 adolescents attending a secondary school in Riga, Latvia. All 
students present during sexual-health classes (grades 10–12 [aged 16–21 years]) 
were included. A self-administered paper-based survey assessed sociodemographic 
factors, sexual behaviours, smear history and knowledge of sexually transmitted 
infections, HPV and HPV vaccine knowledge, and sources of information. 
Results: Overall, 121 surveys were completed (62 by male students and 59 by 
female students). Latvian adolescents lacked awareness of HPV: only 26 (21.5%) 
had heard of HPV (21 [35.6%] female students vs 5 [8.1%] male students; P<0.001) 
and 12 (9.9%) of the HPV vaccine. Eighty (66.1%) participants felt inadequately 
informed about HPV. However, the adolescents partook in high-risk behaviours: 70 
(57.9%) students were sexually active, 26 (37.1%) of whom had already had three or 
more sexual partners. 
Conclusion: Despite the high prevalence of HPV in Latvia, poor knowledge about 
HPV infection among adolescents might explain low uptake of the HPV vaccine by 
this high-risk population. Therefore, educational strategies that highlight the 
consequences of HPV could promote acceptance of vaccination. 
 
 1 INTRODUCTION 
The burden of cervical cancer in Latvia is high. From 1989 to 2011, the incidence 
increased from 8.9 per 100 000 individuals to 23.4 per 100 000 individuals [1]. 
Despite a total population of less than 2 million, 284 new diagnoses were made in 
2012; cervical cancer is now the second most frequent cancer in Latvia to affect 
women aged 15–44 years [2]. 
 
A state-funded national cervical screening program was implemented in 2009 that 
was followed, in 2010, by the introduction of primary prevention in the form of HPV 
vaccination [2]. Persistent infection with high-risk HPV genotypes is responsible for 
almost all cases of cervical cancer [3], as well malignancies of the head and neck, 
anus, vulva, and penis [4]. HPV is one of the most common sexually transmitted 
infections (STIs) that is highly prevalent in the young sexually active population [5]. 
The prevalence of HPV in Eastern Europe is estimated to be as high as 21.4%, 
compared with a global prevalence of 11.7% [6]. Data on HPV prevalence in Latvia 
are scarce; however, estimates published in 2007 showed an overall rate of 26.2% 
[7]. 
 
Primary prevention with HPV vaccination has been successful in other countries with 
high vaccine uptake, such as Australia [8]. Furthermore, these countries have 
reported decreases in the prevalence of vaccine-targeted HPV genotypes, the 
incidence of genital warts, and the incidence of high-grade cervical abnormalities [8]. 
In Latvia, all girls aged 12 years are eligible for fully state-funded HPV vaccination. 
Delivery of the vaccine has been through a combination of schools and primary care 
 health centers [2]. Vaccine coverage data indicate that uptake was approximately 
53.4% in 2012 [9]; however, more up-to-date information has not yet been published. 
 
Knowledge of HPV and its vaccine among adolescent girls is one of the key 
predictors of vaccine uptake in this population [10]. Williams et al. [11] reported that 
adolescent girls had limited understanding and knowledge; therefore, they did not 
fully appreciate their risk of acquiring HPV infection and were unable to provide 
informed consent for HPV vaccination. Knowledge of HPV among European 
adolescents was previously found to be poor in a systematic review [12]. 
Nonetheless, that analysis did not include data from Latvia. 
 
The aim of the present study was to determine the level of knowledge regarding HPV 
and its vaccine among a group of Latvian adolescents 5 years after the introduction 
of the national vaccination program. 
 
2 MATERIALS AND METHODS  
A cross-sectional survey was conducted in a 2-week period in September 2015 at a 
secondary school in Riga, Latvia. School selection was based on the requirement to 
include students who were eligible for HPV vaccination (age ≥12 years) and was 
narrowed down by the established associations of the Latvian coauthors (KP and 
KS). Approval for the present study was obtained from the ethics commission board 
of the University of Latvia, Riga. Participant consent was implied by completion of 
the survey. 
 
 A paper-based survey was administered to students (grades 10–12 [aged 16–
21 years]) during sexual-health teaching sessions. Students attending these classes 
were selected for the present analysis because they were felt to be of the most 
culturally and ethically acceptable age to administer a survey related to sexual-health 
behaviors and STIs. All students who attended the sessions were eligible for 
inclusion in the present study. The anonymous survey was distributed at the 
beginning of the session and the students were given 20 minutes to complete it. 
 
The survey was developed following an extensive literature search of published 
survey studies on HPV and HPV vaccination knowledge among adolescents [12]. 
Appropriate questions were selected [13] and adapted for the Latvian population. 
The survey was developed in English and then translated into Latvian. 
 
The final survey comprised six sections that assessed sociodemographics, smoking 
status, sexual behaviors, smear history and STI knowledge, HPV and HPV vaccine 
knowledge, and sources of HPV-related information. Most of the 30 questions 
included in the survey were closed and had a multiple-choice answer format. The 
knowledge questions had a “true/false/do not know” answer format. The responses 
were numerically coded for the analysis. 
 
The data were analyzed using SPSS version 22 (IBM, Armonk, NY, USA). 
Descriptive statistics were generated for the responses. The χ2 or Fisher exact tests 
were used as appropriate for the analysis. The P values were assessed using two-
sided tests, with statistical significance taken as a cutoff of less than or equal to 0.05. 
Each survey question was analyzed individually to account for missing responses. 
  
3 RESULTS 
Three sexual health sessions were held for each grade (30 students per session), 
resulting in a total sample size of 270. The surveys were completed by 121 students 
(44.8% response rate); 62 (51.2%) respondents were male and 59 (48.8%) were 
female. 
 
The sociodemographic characteristics of the participants are outlined in Table 1. 
Almost all participants were of white Latvian ethnic origin. Table 2 shows smoking 
status and sexual behaviors. All five students aged 19 years or older and 45 (73.8%) 
of the 61 students aged 18 years were sexually active, compared with 20 (36.4%) of 
55 aged 16–17 years (P<0.001). Two (40.0%) students aged at least 19 years 
reported having had three or more sexual partners. 
 
Condoms were the most popular form of contraception among both male and female 
participants (Table 2). Although only 4 (5.7%) of the 70 sexually active participants 
stated that they did not use any contraception, 26 of 66 students who did use 
contraception (39.4%) disclosed that they did not use it on every occasion. 
 
Eight (13.6%) female participants stated they had previously received a cervical 
smear test; 12 (20.3%) were unsure whether or not they had undergone such 
testing. The median age at first smear test was 17 years (range 14–18). 
 
The participants’ knowledge of STIs is presented in Table 3. Some students were 
unable to name even one STI. The inability to name any STIs decreased with 
 increasing age: 3 (33.3%) of 9 aged 16 years could not name one, compared with 8 
(17.4%) of 46 aged 17 years, and 4 (6.6%) of 61 students aged 18 years (P=0.042). 
All participants aged older than 19 years could recall at least one STI. There was no 
difference between the sexes in the ability to name STIs (P=0.240) (Table 3). The 
most commonly named STI was HIV/AIDs; few students named HPV (Table 3). In 
all, 26 (21.5%) respondents had heard of HPV, with female students exhibiting 
greater awareness than male students (P<0.001) (Table 3). 
 
Among the 26 participants who had heard of HPV, more than two-thirds correctly 
identified sexual intercourse as a mode of transmission and approximately one-
quarter correctly identified genital skin-to-skin contact (Table 3). Some participants 
erroneously stated that HPV transmission occurs through blood transfusion and the 
use of public toilets. The use of condoms, vaccination, and good personal hygiene 
were thought to confer protection against HPV. When asked about conditions 
caused by HPV, 19 (73.1%) students knew of the association with cervical cancer, 
with female students having a greater level of awareness than male students 
(P=0.010) (Table 3). Few participants were aware of the association with genital 
warts and none identified the link with penile cancer; one-fifth thought that HPV was 
the cause of HIV/AIDs. 
 
Few students had heard of the HPV vaccine, with awareness more common among 
female participants than male participants (P=0.007) (Table 3). Four (3.3%) 
participants (all female) reported having received the vaccine. The students’ 
responses revealed that they believed the age at which HPV vaccination is 
recommended in Latvia ranged from 11 to 18 years. Assessment of the detailed HPV 
 knowledge section of the survey revealed that six of the 11 female students who had 
heard of the vaccine had left the questions unanswered. By contrast, the one male 
student had selected the “not sure” option for all the questions. Among the five 
female students who had attempted to answer these questions, four were aware of 
the three-dose vaccine schedule and appreciated the level of protection offered by 
vaccination; three correctly identified the need for cervical screening and the 
reduced, but not eliminated, risk of cervical cancer following vaccination. Four of the 
female students understood that the HPV vaccine does not provide protection 
against all STIs. 
 
Overall, 5 (4.1%) students felt adequately informed about HPV, whereas 80 (66.1%) 
disagreed that they were adequately informed. The most popular sources of 
information about HPV were the internet, school, and doctors (Table 3). 
 
No association was found between HPV awareness and other sociodemographic 
factors (Table 4). 
 
4 DISCUSSION 
The present study demonstrated that awareness of HPV and its vaccine among 
Latvian adolescents was poor. Detailed knowledge was also lacking; however, it was 
difficult to draw any firm conclusions given that so few of the participants had even 
heard of HPV or the vaccine. 
 
Although most of the respondents correctly identified sexual intercourse as the mode 
of viral transmission, recognition of the role of genital skin-to-skin contact was 
 undervalued. Other researchers have noted similar misconceptions among 
adolescents, including the belief that transmission occurs through the use of public 
toilets and poor intimate hygiene [14]. Most of the students enrolled in the present 
study were knowledgeable about the causative relationship between HPV and 
cervical cancer, but not of that between HPV and genital warts or penile cancer. One 
possible explanation for this is that, when the HPV vaccine was introduced, the 
emphasis might have been on its role in the prevention of cervical cancer rather than 
any other association. Alternatively, it could stem from the belief that, by minimizing 
the connection of HPV with genital warts, the stigma associated with this condition 
as an STI might be reduced and so vaccine acceptance would be increased [15]. 
 
Female sex was the only factor that correlated with increased awareness of HPV 
and the HPV vaccine in the present study. This finding was in agreement with 
previous studies in both adolescent [12] and adult populations [16]. Thus far, female 
individuals have been the main focus for prevention of HPV infection and/or its 
resultant conditions. However, there is now increased appreciation of the equal 
burden of HPV infection among male individuals and the possible serious long-term 
consequences with regards to the risk of malignancies of the anus, penis, oral cavity, 
and oropharynx [4]. To address this situation, and increase herd immunity, the HPV 
vaccine is being offered to male adolescents in the USA, Canada, Australia, and 
Austria [17]. However, the vaccine is not currently recommended for male 
adolescents in Latvia. 
 
The present study found that general awareness of STIs was deficient, with some 
participants unable to recall even one STI. This result was surprising given that the 
 survey had been administered during a sexual health class. HIV/AIDS were by far 
the most commonly mentioned STIs, which is probably reflective of the extensive 
global awareness campaigns for HIV/AIDS that have taken place since the 1980s 
[18]. Education about HIV/AIDS appears to have eclipsed that of other STIs, even 
though the prevalence of HPV among adolescents is higher than that of HIV/AIDS 
[19]. By contrast with HPV awareness, no sex-related difference was found with 
regard to awareness of STIs in general among participants in the present study. 
 
The high rates of sexual activity (including the total number of partners) reported by 
the present study participants indicated that Latvian adolescents engage in high-risk 
behaviors. Multiple sexual partners increases the chance of both acquisition and 
persistence of infection with high-risk HPV genotypes [20]. Most respondents stated 
that they used contraception; however, approximately two-fifths admitted that this 
practice was not always the case. Condoms were the most frequently used form of 
contraception. Using condoms might not necessarily prevent infection with HPV, as 
infection can occur and/or be transmitted from an epithelial surface that is not 
covered; nevertheless, this method could still provide protection against the 
development of HPV-related conditions [21]. 
 
Although approximately 50.0% of the respondents in the present study knew that the 
HPV vaccine could reduce the risk of infection, only four female students had 
undergone vaccination. This low level of uptake was reported despite the fact that 
the vaccine has been offered free of charge to all Latvian girls aged 12 years since 
2010 [2]; therefore, most of the female students in the present cohort would have 
been eligible for free vaccination. Increased vaccine-related knowledge positively 
 correlates with vaccine uptake [10]. Additionally, attitudes and perceptions of the 
parents to HPV vaccination are believed to play a part [22]. Latvian parents’ attitudes 
toward the HPV vaccine have not been explored; however, uptake of cervical cancer 
screening is suboptimal [23], with maternal screening behaviors linked to HPV-
vaccine initiation [24]. 
 
The recommended age for commencement of cervical cancer screening in Latvia is 
25 years [1]. Nonetheless, eight of the females enrolled in the present study had 
already undergone a cervical smear test (none of these students had received the 
HPV vaccine). This observation suggests that this particular subgroup either 
themselves or through the beliefs of their parents appreciated the need to prevent 
cervical cancer but believed that secondary prevention is superior to primary 
prevention. 
 
Most of the students in the present study felt inadequately informed about HPV. The 
main sources of knowledge were the internet, school, and doctors. Communicating 
HPV-related knowledge to adolescents is a challenge and the optimum method to 
achieve this aim has yet to be identified [25]. Physicians find it difficult to talk about 
the HPV vaccine and are less likely to endorse it than other childhood vaccines [26], 
resulting in a lowered intention to be vaccinated among patients. 
 
The present study had some limitations. The sample size is fairly small and therefore 
the representativeness of these data could be questioned. However, the data have 
provided some insight for this previously unstudied group. An element of bias might 
have been introduced by administering the survey during a sexual-health class. 
 Nonetheless, the students did not perform very well, despite this potential 
advantage. The low rate of survey completion could indicate disengagement of the 
students with the topic of sexual health, because despite been given an allocated 
time during the class to complete the survey, more than half opted not to do so. 
Interpretation of the detailed HPV knowledge questions was limited; few students 
had heard of HPV or its vaccine, and many left the knowledge questions 
unanswered (although this finding in itself might be perceived as lack of knowledge). 
 
In summary, uptake of the HPV vaccine must be greatly increased among Latvian 
adolescents to achieve a substantial impact on the high prevalence of HPV infection 
in this country. Vaccine acceptance might be enhanced, and participation in high-risk 
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 Table 1 Sociodemographic characteristics.a 
Characteristic Total (n=121) Male students (n=62) Female students (n=59) 
Age, y b 18 (16–21) ND ND 
Ethnic origin b    
White Latvian 119 (99.2) 61 (100.0) 58 (98.3) 
Asian 1 (0.8) 0 1 (1.7) 
Religion c    
Roman Catholic 22 (18.6) 14 (23.7) 8 (13.6) 
Lutheran 37 (31.4) 15 (25.4) 22 (37.3) 
Christian (other) 5 (4.2) 4 (6.8) 1 (1.7) 
Jewish 2 (1.7) 0 2 (3.4) 
Hindu 2 (1.7) 1 (1.7) 1 (1.7) 
Buddhist 3 (2.5) 0 3 (5.1) 
Prefer not to say 10 (8.5) 5 (8.5) 5 (8.5) 
Atheist 17 (14.4) 11 (18.6) 6 (10.2) 
Other (not specified) 20 (16.9) 9 (15.3) 11 (18.6) 
Abbreviation: ND, not determined. 
a Values are given as median (range) or number (percentage). 
b One response from male student missing. 
c Three responses from male students missing. 









Do you smoke?    0.909 
Yes 18 (14.9) 9 (14.5) 9 (15.3)  
No 103 (85.1) 53 (85.5) 50 (84.7)  
Have you been sexually 
active? 
   0.249 
Yes 70 (57.9) 39 (62.9) 31 (52.5)  
No 51 (42.1) 23 (37.1) 28 (47.5)  
No. of sexual partners c    0.435 
1 27 (38.6) 14 (35.9) 13 (41.9)  
2 17 (24.3) 8 (20.5) 9 (29.0)  
≥3 26 (37.1) 17 (43.6) 9 (29.0)  
Type of contraception used 
c 
    
Condoms 60 (85.7) 38 (97.4) 22 (71.0) 0.004 
Oral contraceptive pill 5 (7.1) 0 5 (16.1) NA 
No contraception 4 (5.7) 1 (2.6) 3 (9.7) 0.315 d 
Other 1 (1.4) 0 1 (3.2) NA 
Always uses contraception e    0.599 
Yes 40 (60.6) 22 (57.9) 18 (64.3)  
No 26 (39.4) 16 (42.1) 10 (35.7)  
Abbreviation: NA, not applicable. 
a Values are given as number (percentage), unless indicated otherwise. 
b Calculated using the χ2 test; P≤0.05 was considered statistically significant. 
c Assessed among the male students (n=39) and female students (n=31) who were sexually active. 
d Calculated using the Fisher exact test owing to small sample size. 
e Assessed among the male students (n=38) and female students (n=28) who used contraception. 
 









No. of STIs named    0.240 
0 15 (12.4) 4 (6.5) 11 (18.6)  
1 42 (34.7) 20 (32.3) 22 (37.3)  
2 39 (32.2) 27 (43.5) 12 (20.3)  
3 25 (20.7) 11 (17.7) 14 (23.8)  
Most commonly named STIs c     
HIV/AIDs 96 (90.5) 51 (87.9) 45 (93.8) 0.308 
Syphilis 33 (31.1) 24 (41.4) 9 (18.8) 0.012 
Gonorrhea 24 (22.6) 15 (25.9) 9 (18.8) 0.384 
Herpes 22 (20.8) 13 (22.4) 9 (18.8) 0.643 
HPV 8 (7.5) 2 (3.4) 6 (12.5) 0.137 
Hepatitis 7 (6.6) 3 (5.2) 4 (8.3) 0.699 
Chlamydia 7 (6.6) 3 (5.2) 4 (8.3) 0.699 
Have you heard of HPV?    <0.001 
Yes 26 (21.5) 5 (8.1) 21 (35.6)  
No 81 (66.9) 51 (82.3) 30 (50.8)  
Not sure 14 (11.6) 6 (9.7) 8 (13.6)  
How is HPV transmitted?d,e     
Sexual intercourse 18 (69.2) 3 (60.0) 15 (71.4) 0.628 
Blood transfusion 3 (11.5) 1 (20.0) 2 (9.5) 0.488 
Genital skin-to-skin contact 7 (26.9) 2 (40.0) 5 (23.8) 0.588 
Using public toilets 1 (3.8) 1 (20.0) 0 0.192 
Not sure 6 (23.1) 1 (20.0) 5 (23.8) >0.99 
How can you reduce your risk of 
getting HPV?d,e 
    
Condoms 21 (80.8) 3 (60.0) 18 (85.7) 0.236 
Oral contraceptive pill 0 0 0 NA 
HPV vaccine 13 (50.0) 2 (40.0) 11 (52.4) >0.99 
Good personal hygiene 9 (34.6) 2 (40.0) 7 (33.3) >0.99 
Antibiotics 0 0 0 NA 
Do not know 3 (11.5) 1 (20.0) 2 (9.5) 0.488 
Which conditions are caused by 
HPV?d,e 
    
Cervical cancer 19 (73.1) 1 (20.0) 18 (85.7) 0.010 
Genital warts 7 (26.9) 3 (60.0) 4 (19.0) 0.101 
HIV/AIDs 5 (19.2) 1 (20.0) 4 (19.0) >0.99 
Hepatitis 2 (7.7) 1 (20.0) 1 (4.8) 0.354 
Infertility 4 (15.4) 0 4 (19.0) 0.555 
Penile cancer 0 0 0 NA 
None of the above 0 0 0 NA 
Have you heard of the HPV 
vaccine? 
   0.007 
Yes 12 (9.9) 1 (1.6) 11 (18.6)  
No 84 (69.4) 47 (75.8) 37 (62.7)  
Not sure 25 (20.7) 14 (22.6) 11 (18.6)  
Have you had received the HPV 
vaccine? 
   0.081 
Yes 4 (3.3) 0 4 (6.8)  
No 72 (59.5) 36 (58.1) 36 (61.0)  
Not sure 45 (37.2) 26 (41.9) 19 (32.2)  
Can boys have the HPV vaccine?    0.562 
Yes 6 (5.0) 3 (4.8) 3 (5.1)  
No 4 (3.3) 1 (1.6) 3 (5.1)  
Not sure 111 (91.7) 58 (93.5) 53 (89.8)  
Sources of HPV-related     
 information f 
Parents 4 (5.8) 0 4 (10.0) 0.133 
School 24 (34.8) 10 (34.5) 14 (35.0) 0.964 
Doctors 17 (24.6) 6 (20.7) 11 (27.5) 0.517 
TV 8 (11.6) 5 (17.2) 3 (7.5) 0.266 
Radio 1 (1.4) 1 (3.4) 0 0.420 
Magazines and/or newspapers 3 (4.3) 1 (3.4) 2 (5.0) >0.99 
Internet 26 (37.7) 9 (31.0) 17 (42.5) 0.332 
Abbreviations: STI, sexually transmitted infection; NA, not applicable. 
a Values are given as number (percentage), unless indicated otherwise. 
b Calculated using the χ2 or Fisher exact test; a P value ≤0.05 was considered statistically significant. 
c Among the 106 participants who named ≥1 STI (58 male, 48 female). 
d Among the 26 participants who had heard of HPV (5 male, 21 female). 
e Participants were asked to select all of the true options. 
f Among 69 participants (29 male, 40 female). 
 Table 4 Associations between sociodemographic factors and awareness of HPV.a 
Variable Have you heard of HPV? P value b 
Yes No 
Age, y   0.419 
≤17 10 (18.2) 45 (81.8)  
≥18 16 (24.2) 50 (75.8)  
Religion   0.479 
Roman Catholic 2 (9.1) 20 (90.1)  
Lutheran 10 (27.0) 27 (73.0)  
Other c 6 (18.8) 26 (81.3)  
Prefer not to say 2 (20.0) 8 (80.0)  
Atheist 5 (29.4) 12 (70.6)  
Smoking status   >0.99 d 
Non-smoker 22 (21.4) 81 (78.6)  
Smoker 4 (22.2) 14 (77.8)  
No. of sexual partners   0.088 
0 9 (17.6) 42 (82.4)  
1 3 (11.5) 23 (88.5)  
2 7 (41.2) 10 (58.8)  
≥3 7 (26.9) 19 (73.1)  
a Values are given as number (percentage), unless indicated otherwise. 
b Calculated using the χ2 test; P≤0.05 was considered statistically significant. 
c Outcomes for variables were aggregated to form large groups to account for outliers. 
d Calculated using the Fisher exact test owing to small sample size. 
